Skip to main content
. 2020 Mar 24;12:24. doi: 10.1186/s13098-020-00533-3

Fig. 1.

Fig. 1

Time course of HbA1c, BMI, HOMA-IR, and log hsCRP in patients treated with daily DPP4 inhibitors and weekly omarigliptin. Red circles, omarigliptin; blue squares, daily DPP4 inhibitors (control group). Data are presented as mean ± SD. Group differences between control and omarigliptin were analyzed using repeated measures ANOVA (*p < 0.05, p = 0.73536, 0.2176, 0.01409, and 0.00712 for HbA1c, BMI, HOMA-IR, and log hsCRP, respectively)